title: Nuclear receptors as pharmaceutical targets: rise of FXR and rebirth of PPAR?
authors.forename: Daniel
authors.initials: D
authors.lastname: Merk
authors.forename: Manfred
authors.initials: M
authors.lastname: Schubert-Zsilavecz
mesh_terms: D006801:Humans; D008024:Ligands; D008659:Metabolic Diseases / Q000188:drug therapy; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists* / Q000378:metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000037:antagonists & inhibitors* / Q000378:metabolism; D045162:Thiazolidinediones / Q000737:chemistry / Q000627:therapeutic use; D000099150:Receptor, Farnesoid X-Activated
chemical_list: D008024:Ligands; D047492:Peroxisome Proliferator-Activated Receptors; D018160:Receptors, Cytoplasmic and Nuclear; D045162:Thiazolidinediones; D000099150:Receptor, Farnesoid X-Activated